Targeting cell migration in rheumatoid arthritis

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
• Chemokines and their receptors play a crucial role in immune cell trafficking and inflammatory processes in RA.

Purpose of the Study:

• To review past failures, current prospects, and challenges in targeting chemokines and their receptors for RA therapy.
• To provide an update on the therapeutic landscape for chemokine-targeted drugs in rheumatoid arthritis.

Main Methods:

• Review of clinical trial data for small molecule antagonists and neutralizing antibodies targeting chemokine receptors (CCR1, CCR5, CXCL10).
• Analysis of laboratory and clinical research identifying novel chemokine targets (CCL19, CXCL13, CXCL12) in RA.
• Evaluation of recent findings on posttranslational chemokine modifications and their impact on chemokine networks.

Main Results:

• Clinical trials targeting CCR1, CCR5, and CXCL10 in RA have yielded some encouraging results.
• CCL19, CXCL13, and CXCL12, along with their receptors, are identified as potential future therapeutic targets.
• Understanding of chemokine network complexity in inflamed tissues is growing, but significant knowledge gaps remain.

Conclusions:

• Despite previous setbacks, there is optimism for developing chemokine-targeting drugs for RA.
• A deeper understanding of chemokine networks in inflamed joints is essential for successful therapeutic development.